FDA Approves Zydus’ Phase IIb trial of Usnoflast for ALS Treatment

The trial will test 50mg and 75mg doses of the therapy against a placebo. he US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 inflammasome inhibitor, Usnoflast, for amyotrophic lateral sclerosis (ALS) treatment.

The multi-centre, placebo-controlled, double-blind trial will assess the therapy’s safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients.

Sean M Healey & AMG Centre for ALS director professor Merit Cudkowicz will lead the study as principal investigator. The trial aims to enrol 210 subjects and will test two different therapy doses of 50mg and 75mg against a placebo.

The trial will last 36 weeks, followed by an open-label extension for an additional 16 weeks.

The trial’s primary endpoint is the change in the ALS Functional Rating Scale-Revised (ALSFRS-R) total score from baseline to week 36. Secondary endpoints include changes in slow vital capacity (SVC) and neurofilament levels in the cerebrospinal fluid (CSF).

In addition, the study will analyse biomarkers such as high-sensitivity C-reactive protein (hs-CRP), interleukin (IL)-18, IL-6, IL-1β, NLRP3, and serum amyloid A (SAA).Zydus Lifesciences chairman Pankaj Patel said: “We are excited to report the approval from the USFDA to initiate this randomised, double-blind, placebo-controlled Phase IIb clinical trial in ALS patients. Zydus is committed to unlocking new frontiers in neuroscience and developing transformative breakthrough medicines.”

Also known as ZYIL1, Usnoflast has been explored in various pre-clinical studies for neuroinflammation and other conditions. The company has also secured orphan drug status for the therapy from the FDA for treating Cryopyrin Associated Periodic Syndrome (CAPS).

ALS is characterised by rapid neurodegeneration, it leads to severe physical disabilities and death, primarily due to respiratory failure.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!